Newcourt (NASDAQ:NCAC) announced in an 8-K this morning that it has secured an aggregate of $12.5 million in convertible notes for its merger with psychedelic medicine company Psyence (CSE:PSYG).
The notes will consist of up to four senior secured convertible notes, issuable to the purchaser at or after the closing, in exchange for up to $10 million in subscription amounts.
The issuance of the tranche notes each involves a principal amount of $3.12 million in exchange for subscription amounts totaling $2.5 million.
While the first tranche note is contingent upon the completion of the combination with Psyence, the second tranche note allows for adjustments based on the market value traded. The purchaser may invest additional amounts over time to fulfill the second tranche note.
The third and fourth tranche notes, if issued, follow a similar structure with a principal of $3.12 million exchanged for $2.5 million in subscription amounts.
Interest will begin accruing at 8.0% per annum based on the outstanding principal amount of the note, payable monthly in cash or common shares.
Additionally, in consideration of the willingness of the purchaser, shareholders will deliver a structuring fee of common shares with 1.3 million structuring shares delivered at the first tranche closing. Following the closing, 1.7 million structuring shares will be delivered under the terms outlined in the call option agreements to be entered into between the purchaser and certain shareholders.
In connection with the securities purchase agreement, the sponsor and Psyence Group will enter into a lock-up agreement for 180 days following the closing of the combination.
Furthermore, the parties agreed to waive the minimum cash closing condition of $20 million and the investment condition stating that the PIPE should be ready to occur concurrently with the closing.
Newcourt announced its deal with Psyence in January 2023. As of now, the SPAC faces a completion deadline of January 22, but is looking to hold a shareholder meeting to extend its timeline. The Canada-listed company is developing psychedelic drug candidates to potentially treat patients in palliative care and those with severe psychological conditions.
At the SPAC of Dawn As a rough week in the market comes to a close, at least one de-SPAC has some cause to show off. Many fashion brands were among the hard hit in recent days and not simply for macro reasons. Luis Vuitton-owner LVMH (PA:MC) dropped this week after an earnings miss led...
Shepherd Ave Capital Acquisition Corp. (Nasdaq: SPHAU) is the latest SPAC to file to IPO, making 24 new registration statements that have filed since June 1, 2024. So far, only two of those 24 have gone public, but it does indicate an active August. In SPACLand at least, August is never slow. As for Shepherd...
At the SPAC of Dawn SPACs have now priced 20 IPOs seven months into 2024 with an eye on beating 2023’s total of 31 IPOs. With a little more than 5 months left in the year, it’s expected that SPACs should at least match that number by only needing to price roughly two IPOs per...
DT Cloud Star announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “DTSQU”, Thursday, July 25, 2024. The new SPAC aims to combine with an established business with long-term financial visibility, but has not limited itself to a particular industry or sector....
Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...